**Supplementary Figure 1. The titer of anti-MDA5 Ab is determined in patients with COVID-19 or anti-MDA5 Ab-related DM.** ELISA analysis was employed in the plasma samples collected from COVID-19 patients (n=274) and anti-MDA5 Ab-related DM (n=5). Plasma samples from healthy donors served as control (n=50). *P* values were determined by using unpaired, two-sided Mann-Whitney *U*-test. *P*<0.001, \*\*\*; *P*<0.0001, \*\*\*\*.

**Supplementary Figure 2. The titer of anti-MDA5 Ab is evaluated in the sequential samples from patients with severe COVID-19.** 20 cases of COVID-19 patients were included in this determination. Of them, sequential samples were collected from DFSO-8 (n=3), DFSO-9 (n=2), DFSO-10 (n=1), DFSO-11 (n=8), DFSO-12 (n=4), DFSO-13 (n=1), and DFSO-14 (n=1), respectively. Each dot represents 4 time-points arranged by intervals of five days and the titer of anti-MDA5 Ab is indicated.

****

**Supplementary Figure 1**

****

**Supplementary Figure 2**